Thioredoxin: a key factor in cold tumor formation and a promising biomarker for immunotherapy resistance in NSCLC

Thioredoxin: a key factor in cold tumor formation and a promising biomarker for immunotherapy resistance in NSCLC

Abstract Immune checkpoint blockade (ICB) therapy has shown promising clinical efficacy in cancer treatment, but only a subset of patients experience significant therapeutic responses. Tumor cells respond to internal and external stresses, such as hypoxia and nutrient deprivation, by activating the...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiayi Hu, Yilimunuer Abulimiti, Haiyang Wang, Dianyu Yang, Xu Wang, Yang Wang, Ping Ji
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Respiratory Research
Subjects:
NSCLC
Immune checkpoint Blockade (ICB) therapy
Thioredoxin (TXN)
Online Access:https://doi.org/10.1186/s12931-025-03259-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items